WDR77 and prostate carcinoma: Clearly, further insight into the molecular mechanisms underlying silencing of PKG-Iβ and cytoplasm localization of p44 in human prostate cancer will help to facilitate the development of therapeutic strategies, involving reexpression of PKG-Iβ and nuclear translocation of p44, for the treatment of prostate cancer.